Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study
In a large real-world cohort of acute and chronic coronary syndrome undergoing cardiac rehabilitation, over 10 % of patients were theoretically eligible for IPE based on clinical trial criteria. However, less than 1 % met current AIFA eligibility conditions due to added restrictions, highlighting a significant barrier to implementation in clinical practice.
Authors
- Fabrizio Oliva
- Simona Pierini (ORCID: https://orcid.org/0000-0003-1595-6681)
- G Prencipe (ORCID: https://orcid.org/0009-0005-7660-9183)
- Chiara Tognola (ORCID: https://orcid.org/0009-0003-7782-8949)
- Antonella Moreo (ORCID: https://orcid.org/0000-0003-3150-3885)
- Viola Dadone
- Maddalena Lettino
- Alessandro Maloberti (ORCID: https://orcid.org/0000-0002-2612-6264)
- Cristina Giannattasio
- Giuseppe Trocino
- Piera Angelica Merlini
- Giovanna Viola
- Filippo Brucato (ORCID: https://orcid.org/0009-0009-2465-3181)
- M Bellomare
Institutions
- Milano Metropoli Development Agency (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Azienda Ospedaliera San Gerardo (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.ijcard.2025.134046
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00